Watson-Actavis talks confirmed: merging geography and biosimilars
This article was originally published in Scrip
It has been confirmed to Scrip by sources very close to the company that two of the world's leading generic medicines companies are negotiating a merger to create a company with generic drug sales approaching €6 billion. While the official line from both companies was no comment', various sources confirmed that a negotiation was taking place, that matters were close to being finalised, and that the expectation was that a deal would be concluded in the next few weeks.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.